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RUBRIC OF CRITERIA

INTRODUCTION
▪Prostate cancer (PCa) is one of the most widespread cancers diagnosed in men
in the United States and is the second leading cause of cancer-related deaths
worldwide [Bray, 2018]. PCa will be a major cancer-related burden both socially
and economically in the near future [Bray 2018]. It has been shown that dietary
intake of natural anti-inflammatory agents are capable of inhibiting cancer
progression [Jang, 1997] [ Martínez-Martínez, 2019] [Peisch, 2017] (Figure 1), but
due to the nature of dietary studies it is difficult to accurately conclude that diet is
capable of impacting chronic diseases and mortality [Schwingshackl, 2017].This
critical analysis aims to collect and evaluate literature focused on prostate cancer
progression and the natural anti-inflammatory agents of lycopene and the
Mediterranean diet (MedD).

METHODS
▪Data Sources: An electronic search included the following databases: PUBMED,
EBSCOhost Web, Scopus and clinical trials registry platforms were used to survey
the important literature.
▪ Study Categorization:
▪ Once studies have been selected, they will be categized based on the type of
study. The categories will be:
▪ Randomized Control trials (RCTs)
▪ Cohort Studies
▪ Case-control studies
▪ Cross-sectional studies

Figure 1: Different treatment options available for prostate cancer and
different stages which natural anti-inflammatory agents are capable of
effecting cancer progression

▪RCT Study Selection: Study inclusion criteria were as follows: 1) uniform form of
measurement for evaluating the risk of prostate cancer/ current state of prostate
cancer in patients; 2) patients treated in a clinical or observational setting; 3) an
experimental group in which subjects clearly underwent an intervention focused
on preventing or reducing prostate cancer initiation or progression; 4) a clearly
defined control group in which subjects received either a placebo or standard
care therapy; and 5) an outcome measure assessing the risk or current state of
prostate cancer.

Conclusions: Despite an insufficiency of high-quality clinical
investigations, current literature suggest that:
1) adherence to the MedD may be inhibitory for both PCa incidence and
progression, 2) lycopene administration may be inhibitory for PCa
incidence, but not progression.

▪Cohort Studies, Case-control Studies, and Cross-Sectional Studies Selection:
Study inclusion criteria were as follows: 1) uniform form of measurement for
evaluating the risk of prostate cancer/ current state of prostate cancer in patients;
and 2) an outcome measure assessing the risk or current state of prostate cancer.
▪Data Extraction: For randomized control trials a qualitative analysis was done to
gather and summarize effects of identified interventions according to the
recommended methodology from the Cochrane Handbook [Higgins 2011]. For
all other types of studies (Cohort Studies, Case-control studies, and Crosssectional studies) a rubric of criteria was created and used to analyze these
studies (Figure 2).
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Figure 2: Assessment of Study Bias for Cohort Studies, Case-control
Studies, and Cross-Sectional Studies

